
NYSEHealthcareDrug Manufacturers - General
ข้อมูลล่าสุด
US$46.50
−US$0.04 · -0.09%
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
ราคาปิดก่อนหน้า
US$46.50
−US$0.04 · -0.09%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
ช่วงราคารายวัน
ปัจจุบัน US$46.50
ช่วง 52 สัปดาห์
ปัจจุบัน US$46.50
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ซื้อ
มูลค่า
98
มูลค่าน่าสนใจมาก
ความเชื่อมั่น
54
ผสม
ความเสี่ยง
23
ความเสี่ยงปานกลาง
โมเมนตัม
48
เป็นกลาง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
ช่วงราคารายวัน
ปัจจุบัน US$46.50
ช่วง 52 สัปดาห์
ปัจจุบัน US$46.50
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (GBP) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 32.67B GBP | 31.38B GBP | 30.33B GBP | 29.32B GBP | 24.7B GBP |
| ต้นทุนสินค้าขาย | 9.02B GBP | 9.05B GBP | 8.57B GBP | 9.55B GBP | 8.16B GBP |
| กำไรขั้นต้น | 23.65B GBP | 22.33B GBP | 21.76B GBP | 19.77B GBP | 16.53B GBP |
| การวิจัยและพัฒนา | 7.53B GBP | 6.4B GBP | 6.22B GBP | 5.49B GBP | 5.02B GBP |
| การขาย ทั่วไป และธุรการ | 9.09B GBP | 11.02B GBP | 9.39B GBP | 8.37B GBP | 7.07B GBP |
| ค่าใช้จ่ายในการดำเนินงาน | 15.31B GBP | 18.31B GBP | 15.02B GBP | 13.34B GBP | 12.18B GBP |
| รายได้ดอกเบี้ย | 56M GBP | 67.39M GBP | 40M GBP | 64.27M GBP | 28M GBP |
| ดอกเบี้ยจ่าย | 687M GBP | 657.58M GBP | 775M GBP | 855.53M GBP | 784M GBP |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 2.31B GBP | 2.55B GBP | 2.29B GBP | 2.15B GBP | 2.12B GBP |
| รายได้จากการดำเนินงาน | 8.34B GBP | 4.02B GBP | 6.75B GBP | 6.43B GBP | 4.36B GBP |
| รายได้สุทธิ | 5.72B GBP | 2.58B GBP | 4.93B GBP | 14.96B GBP | 4.39B GBP |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 11 ต.ค. 2569.
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
State Street SPDR Portfolio Developed World ex-US ETFSPDW113.46M0.28%40.46B USD0.03%US$49.98+0.64%
Avantis International Equity ETFAVDE67.27M0.35%19.22B USD0.23%US$89.80+0.58%
Fidelity Enhanced International ETFFENI52.52M0.46%11.47B USD0.28%US$39.69+0.43%
VanEck Pharmaceutical ETFPPH44.46M4.34%1.04B USD0.36%US$110.49+1.20%
First Trust Value Line Dividend Index FundFVD29.29M0.38%7.62B USD0.62%US$47.66+0.13%
GMO International Value ETFGMOI15.11M2.30%654M USD0.60%US$39.18+0.26%
Hartford Multifactor Developed Markets (ex-US) ETFRODM14.24M0.89%1.61B USD0.29%US$40.82+0.25%
Avantis International Large Cap Value ETFAVIV10.69M0.53%2.02B USD0.25%US$79.00+0.34%
State Street SPDR Portfolio Developed World ex-US ETFSPDW
Avantis International Equity ETFAVDE
Fidelity Enhanced International ETFFENI
VanEck Pharmaceutical ETFPPH
First Trust Value Line Dividend Index FundFVD
GMO International Value ETFGMOI
Hartford Multifactor Developed Markets (ex-US) ETFRODM
Avantis International Large Cap Value ETFAVIVเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน